Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

June 10, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-120 for treatment of patients with acute myelogenous leukemia (AML). AG-120 is an oral, first-in-class IDH1 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH1 mutation.

Flagship Ventures Welcomes 16 VentureLabs® Fellows Commencing Its Seventh Annual Fellowship Program

Flagship Ventures Welcomes 16 VentureLabs® Fellows Commencing Its Seventh Annual Fellowship Program

June 10, 2015

Program Expands to Accelerate Venture Creation

CAMBRIDGE, Mass., June 10, 2015 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced the start of its seventh VentureLabs® Fellowship Program, a rare opportunity for graduate and post-graduate students to experience VentureLabs' unique approach to innovation, company creation, and entrepreneuring.

Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout

Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout

June 10, 2015

The first immunotherapeutic candidate from Selecta's proprietary Synthetic Vaccine Particle (SVP) Platform, SEL-212 aims at addressing the high unmet needs of refractory and tophaceous gout patients

Selecta's SVP immunotherapeutic platform has broad applications, including inhibition of immunogenicity for biologic therapies and antigen-specific treatment of allergies and autoimmune diseases

Pronutria Biosciences Announces Key Additions to Executive Team

Pronutria Biosciences Announces Key Additions to Executive Team

June 2, 2015

Anders Gram, Ph.D., appointed Chief Production and Global Supply Chain Officer and Larry Bell, M.D., appointed Global Head of Regulatory Affairs and Pharmacovigilance

Seres Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of SER-109 for the Prevention of Recurrent Clostridium difficile Infection in Adults

Seres Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of SER-109 for the Prevention of Recurrent Clostridium difficile Infection in Adults

May 28, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company, announced today the enrollment and dosing of the first patient in its Phase 2 clinical study of SER-109, an investigational oral microbiome therapeutic for the prevention of recurrent Clostridium difficile infection (CDI) in adults. The objective of the Phase 2 study is to further assess the efficacy and safety of SER-109, Seres’ leading development candidate.

Pronutria Biosciences Raises $39 Million in Series C Financing

Pronutria Biosciences Raises $39 Million in Series C Financing

May 28, 2015

Proceeds will Advance Clinical Development Programs for Multiple Therapeutic Areas

CAMBRIDGE, Mass. – May 28, 2015 – Pronutria Biosciences, a clinical stage biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, today announced the successful completion of a $39 million Series C financing led by new investor Fidelity Management & Research Company and joined by founding investor Flagship Ventures among others.

Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies

Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies

May 27, 2015

Alliance combines Editas’ genome editing technology and expertise and Juno’s extensive CAR T and TCR platforms

Visterra Partners with A*STAR to Develop VIS513, a Monoclonal Antibody for Dengue

Visterra Partners with A*STAR to Develop VIS513, a Monoclonal Antibody for Dengue

May 21, 2015

- Key Development Activities of the Collaboration Will Be Conducted in Singapore -

Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference

Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference

May 18, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced data from several emerging therapeutic discovery programs, as well as data from advancements in its technology platform. Together these data demonstrate the breadth of research underway at Editas Medicine to translate the promise of genome editing technology into new medicines. The data were presented at the 18th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting in New Orleans.

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

May 18, 2015

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designations to luspatercept for two separate indications; the use of luspatercept for the treatment of patients with transfusion dependent beta-thalassemia and the use of luspatercept for the treatment of patients with non-transfusion dependent beta-thalassemia. Celgene and Acceleron are jointly developing luspatercept.